SLRX:NSD-Salarius Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.771

Change

-0.01 (-1.15)%

Market Cap

N/A

Volume

0.02M

Analyst Target

USD 4.43
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-4.61 (-1.07%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

-19.89 (-3.63%)

USD 65.38B
ARGX argenx NV ADR

-19.47 (-3.42%)

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

-7.20 (-2.79%)

USD 30.51B
SMMT Summit Therapeutics PLC

-0.69 (-2.80%)

USD 27.07B
ONC BeiGene, Ltd.

-3.95 (-1.67%)

USD 26.35B
RPRX Royalty Pharma Plc

+0.05 (+0.15%)

USD 18.40B
INSM Insmed Inc

-0.55 (-0.84%)

USD 12.52B
INCY Incyte Corporation

-0.75 (-1.26%)

USD 11.72B
BMRN Biomarin Pharmaceutical Inc

-0.96 (-1.60%)

USD 11.50B

ETFs Containing SLRX

SRET Global X SuperDividend® .. 3.43 % 0.59 %

+0.13 (+0.64%)

USD 0.18B
MORT VanEck Mortgage REIT Inco.. 3.17 % 0.42 %

-0.03 (0.64%)

USD 0.26B
REM iShares Mortgage Real Est.. 3.15 % 0.48 %

-0.03 (0.64%)

USD 0.55B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -58.10% 16% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.10% 16% F 8% B-
Trailing 12 Months  
Capital Gain -80.73% 19% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.73% 19% F 7% C-
Trailing 5 Years  
Capital Gain -99.55% 6% D- 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.55% 6% D- 2% F
Average Annual (5 Year Horizon)  
Capital Gain 93.75% 85% B 93% A
Dividend Return 93.75% 85% B 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 893.45% 12% F 4% F
Risk Adjusted Return 10.49% 64% D 46% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.